Navigation Links
MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
Date:10/10/2007

rmaceutical company committed to the development of new drug candidates and whose current drug candidates include:

-- MCT-125 for the treatment of primary fatigue in MS patients.

-- MCT-175 for the treatment of relapsing-remitting MS.

-- MCT-465 for the treatment of TLR3 positive breast cancers.

-- MCT-475 for the treatment of TLR3 positive cervical cancers.

For more information about MultiCell Technologies, please visit http://www.multicelltech.com

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development of MCT-125, statements regarding selling, using or developing the FA2N-4 cell line and MultiCell's identification of new drug targets. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory
'/>"/>

SOURCE MultiCell Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Barriers will not stop convergence of medical technologies
2. Merge Technologies net loss doubles to $10.1M
3. Making deals with evolving technologies in mind
4. Third Wave Technologies to raise $14.9M through private debt
5. Meier joins Broadlook Technologies as COO
6. Platypus Technologies secures $450K SBIR grant
7. Napier joins board of Third Wave Technologies
8. aOva Technologies raises $3 million
9. Consumer, business technologies face same challenges
10. Promega to get early access to WARF technologies under new agreement
11. Linda Weber to run Fiservs Interactive Technologies unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Transparency Market Research, in its report titled ... by Application - Cancer, Metabolic, CVS, CNS & others, ... - Global Industry Analysis, Size, Share, Growth, Trends and ... therapeutics market was worth US$14.1 billion in 2011 and ... an 8.7% CAGR. , The two main types of ...
(Date:9/29/2014)... METTLER TOLEDO’s new line of XPE ... precision balances as well as automated dosing ... can carry out their daily weighing tasks worry free, ... deliver consistently reliable and compliant results, thanks to new ... of the biggest challenges in analytical and micro-analytical weighing ...
(Date:9/29/2014)... ANGELES , Sept. 29, 2014 ... biopharmaceutical research and development company specializing in oncology, ... Administration (FDA) has granted multiple Orphan Drug Designations ... three indications: glioblastoma multiforme (GBM), small cell lung ... version of the widely-used chemotherapeutic agent, doxorubicin. ...
(Date:9/27/2014)... in the peer-reviewed Journal of Animal Science ... crops has no impact on the health or productivity ... literature and field data sets, the article documents evidence ... GE crops are comparable with those of animals fed ... GE feed crops have become an increasing component of ...
Breaking Biology Technology:Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3New Line of XPE Balances from METLER TOLEDO is Designed for High Performance and Ease of Compliance 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 3CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 4CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 5
... MILWAUKEE - Miller Brewing Co. ... its sourcing processes, consolidate purchases across six U.S. ... those processes, Procuri announced. , ,Procuri, ... such as Blue Cross and Blue Shield Association, ...
... from the University of Wisconsin-Madison and an international consortium ... the first astronomical images obtained by the Southern African ... to the largest optical telescope in the world. , ... built the telescope on a remote mountain plateau, 220 ...
... Wis. -- One of the greatest agricultural and evolutionary ... the answer may lie in a plot of corn on ... new life to ancient genetic material. , ,While many biologists ... of maize, others believe that the differences between teosinte and ...
Cached Biology Technology:Single gene controls key difference between maize and its wild ancestor 2Single gene controls key difference between maize and its wild ancestor 3
(Date:9/29/2014)... "human activities in this area of the world have contributed ... grown for use as a cooking oil and biofuel, while ... the most widely produced edible oil in the world, and ... soybean oil. , The environmental effects of such growth have ... crop, and the preferred method is fire. The clearing often ...
(Date:9/29/2014)... Mountain pine beetles get a bad rap, and ... pine trees over tens of millions of acres in ... , But contrary to popular belief, these pests ... like those that have recently swept through the region. ... the ecological severity of fires than these bark-boring beetles. ...
(Date:9/29/2014)... published online in Behavioral Brain Research provides ... as a result of chronic alcohol exposure that can ... Clinical assessments and research indicate that individuals with alcohol ... can occur when people are actively drinking, when they ... , "Sleep-wake disturbances can last for months, or ...
Breaking Biology News(10 mins):Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... As health professionals search for ways to combat the rise ... mother,s own eating habits and whether she views her ... on whether her child consumes enough fruits and vegetables. ... University,s College of Nursing looked at nearly 400 low-income women ...
... count, and that certainly holds true for the channels ... or molecules of a certain size to pass through, while ... capabilities of transmembrane proteins are highly prized for a number ... individual artificial channels of this size until now. ...
... Australia,s swamp bottlebrush, flowering plants are everywhere. Also ... land-based, plant life. New research published this week ... Sciences provides new insights into their genetic origin, ... diverse flowering plants more than 130 million years ago. ...
Cached Biology News:Mothers' diets have biggest influence on children eating healthy 2Tiny channels carry big information 2Tiny channels carry big information 3What 'pine' cones reveal about the evolution of flowers 2What 'pine' cones reveal about the evolution of flowers 3